Betafectin

(redirected from PGG-glucan)
Also found in: Wikipedia.

Betafectin

A recombinant beta-glucan immunomodulator which was thought to reduce the risk of staphylococcal wound infection. It made it to phase-III clinical trials to prevent serious postoperative infection in GI surgical patients—e.g., for Crohn’s disease or ulcerative colitis.
References in periodicals archive ?
(1994a) A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients.
(1994b) Randomized phase I/II trial of a macrophagespecific immunomodulator (PGG-glucan) in high-risk surgical patients.
(1999) Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations.
(1998) Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity.
(37.) Niederman R, Kelderman H, Socransky S, Ostroff G, Genco C, Kent R, Jr., Stashenko P Enhanced neutrophil emigration and Porphyromonas gingivalis reduction following PGG-glucan treatment of mice.
(46.) Babineau TJ, Hackford A, Kenler A, Bistrian B, Forse RA, Fairchild PG, Heard S, Keroack M, Caushaj P, Benotti P A phase 11 multicen ter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients.
Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients.